Please login to the form below

Not currently logged in


This page shows the latest NKTR-102 news and features for those working in and with pharma, biotech and healthcare.

Nektar hit by breast cancer trial setback

Nektar hit by breast cancer trial setback

Nektar hit by breast cancer trial setback. NKTR-102 failed to meet phase III targets. ... The development is also particularly disappointing for Nektar as NKTR-102 was a wholly owned project.

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Create Health

A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...

Latest intelligence

Theresa Heggie
Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe
Theresa Heggie talks about the biotech’s 16-year path to market, and the promise of its ‘gene silencing’ medicines...
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...